31.07.2013 • News

Dow Chemical EBITDA up 9% in Q2

U.S. chemical giant Dow Chemical saw adjusted EBITDA gain nearly 9% year-on-year to $ 2.1 billion in Q2 2013, thanks mainly to strong business in the Agricultural Science and Performance Plastics segments. The unusually large adjustment reflects a payment of $2.2 from Petrochemical Industries Company of Kuwait in arbitration over the K-Dow joint venture canceled by Kuwait in 2009. Quarterly sales were flat at $14.6 billion. Led by activities in emerging markets that more than offset a decline in Europe, volume growth averaged 9%, said CEO Andrew Liveris. Prices receded by 2%, due in part to currency translations. 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read